Pharmaceutical giants Pfizer and GlaxoSmithkline have merged their respective departments that develop medication to treat HIV to create a new, separate company.
The new company will have a 19%, £1.6bn, global market share in HIV and AIDS medication. The as yet unnamed new unit will be 85-15 weighted in favour of GSK in terms of ownership. “Today marks a definitive step by GSK to renew our focus and deliver more medicines, more efficiently, to people living with…
This content is for subscribers only. Subscribe now for free to read the full article.
Already a subscriber? Login
